Novel mRNA-based Prognostic Index Derived from Differential Expression Analysis Improves Overall Survival Estimates in Glioblastoma

Case ID:

This innovation is a set of biomarkers to predict radiotherapy and chemotherapy outcomes in individual Glioblastoma Multiforme patients to better assess their prognosis and therapy. The method uses gene expression analysis to analyze multiple predictive biomarkers and generate a novel Glioblastoma Prognosis Index to accurately predict the overall survival of the afflicted patient. It can also potentially be used to predict patient responses to drugs that inhibit Wnt signaling pathway. 

Glioblastoma Multiforme (GBM) is the most common and aggressive form of brain cancer and is currently treated through surgical intervention, chemotherapy, and radiotherapy. The effectiveness of chemotherapy and radiotherapy fluctuates depending on the patient. GBM growth has been shown to have positive and negative dependency on different gene expression. Use of predictive biomarkers can help with faster identification of GBM and earlier treatment for better survival outcomes. 


  • Prediction of chemotherapy and radiotherapy effectiveness in GBM patients
  • Glioblastoma prognosis
  • Companion diagnostic for inhibitors to Wnt pathway


  • Provides a more precise prediction of treatment outcomes
  • Application to various signaling pathways
  • Avoids the use of unnecessary or excessive treatments
  • Increased overall survival rates
  • In situ process
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
Eric Weterings
Baldassarre Stea
Daruka Mahadevan
Michael Hammer
Christopher Morrison